Enterprise Value

12.95B

Cash

1.032B

Avg Qtr Burn

N/A

Short % of Float

2.47%

Insider Ownership

1.00%

Institutional Own.

95.42%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
INGREZZA (valbenazine) Details
Huntington's disease, Chorea

Approved

Quarterly sales

INGREZZA (valbenazine) Details
Huntington's disease, Dyskinesia

Approved

Quarterly sales

INGREZZA (valbenazine) Details
Huntington's disease, Chorea, Dyskinesia

PDUFA

Approval decision

Crinecerfont Details
Congenital adrenal hyperplasia

NDA

Submission

Valbenazine Details
Psychiatric disorder, Schizophrenia

Phase 3

Data readout

Valbenazine Details
Neurological disorder, Cerebral Palsy, Dyskinesia

Phase 3

Data readout

Phase 2

Data readout

Phase 2

Data readout

Luvadaxistat Details
Psychiatric disorder, Schizophrenia

Phase 2

Data readout

NBI-1065845 Details
Major depressive disorder

Phase 2

Data readout

Efmody Details
Adrenal Insufficiency

Phase 2

Data readout

Efmody Details
Congenital adrenal hyperplasia

Phase 2

Data readout

NBI-921352 Details
Focal Onset Seizures

Phase 2

Update

NBI-1065846 Details
Major depressive disorder

Phase 2

Update

NBI-1065890 Details
Neurological disorder

Phase 1

Data readout

Phase 1

Data readout